Mark Anthony Tyndall - 01 Jan 2026 Form 4 Insider Report for Keenova Therapeutics plc

Signature
/s/ Mark Tyndall
Issuer symbol
N/A
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
4
Filing time
05 Jan 2026, 18:04:26 UTC
Previous filing
04 Aug 2025
Next filing
26 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tyndall Mark Anthony EVP & CLO and Corp Sec 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER /s/ Mark Tyndall 05 Jan 2026 0001944622

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction Ordinary Shares Options Exercise +6,576 +178% 10,274 01 Jan 2026 Direct F1
transaction Ordinary Shares Tax liability -2,107 -21% 8,167 01 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Restricted Stock Units Options Exercise $0 -6,576 -13% $0.000000 46,031 01 Jan 2026 Ordinary Shares 6,576 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
F2 The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
F3 On February 2, 2024, the Reporting Person was granted 16,413 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.
F4 Reflects that the Reporting Person received 8,836 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.